ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

プラゾシン

Prazosin

HCID 4893
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
19216-56-9
標準SMILES
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
分子式
C19H21N5O4
平均分子量
383.4 g/mol
単同位体質量
383.15935417

概要

Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of furans, a member of piperazines, a monocarboxylic acid amide, an aromatic ether and a member of quinazolines.

名称と識別子

優先名称
Prazosin
IUPAC
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
現地名
プラゾシン
英語名
Prazosin
分子式
C19H21N5O4
分子量
383.4

名称と別名

prazosin19216-56-9FurazosinPrazosinePrazosinaPrazosinum1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazolineDTXSID4049082Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-XM03YJ541DCP-122991
名称をさらに表示
2-[4-(2-フラニルカルボニル)ピペラジノ]-6,7-ジメトキシキナゾリン-4-アミン1-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)-4-(フラン-2-イルカルボニル)ピペラジン(2-フラニル)[4-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)ピペラジン-1-イル]ケトンフラゾシンプラゾシン1-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)-4-(2-フロイル)ピペラジン1-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)-4-(2-フラニルカルボニル)ピペラジン1-(4-アミノ-6,7-ジメトキシ-2-キナゾリニル)-4-(2-フラニルカルボニル)ピペラジン2-フリル4-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)-1-ピペラジニルケトン2-[4-(2-フロイル)ピペラジン-1-イル]-6,7-ジメトキシキナゾリン-4-アミン2-[4-(2-フロイル)ピペラジノ]-6,7-ジメトキシキナゾリン-4-アミン1-(4-アミノ-6,7-ジメトキシキナゾリン-2-イル)-4-[(フラン-2-イル)カルボニル]ピペラジン2-[4-(フラン-2-カルボニル)ピペラジン-1-イル]-6,7-ジメトキシキナゾリン-4-アミンpressinminipressAKOS B020009PrazosinBaseTerazosin-010

物性

構造計算による物性補完中

XLogP
2
極性表面積
107 Ų
水素結合供与体数
1
水素結合受容体数
8
回転可能結合数
4
重原子数
28
形式電荷
0
複雑度
544

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 件

1.3

1.9

Solubility6.93e-01 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Adrenergic alpha-Antagonists; Antihypertensive Agents

Pharmaceuticals

Melting Point · 2 件

277-280

279 °C

Physical DescriptionSolid
Dissociation Constants6.54
Collision Cross Section · 2 件

192.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

186.41 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
278 · 278-280°C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Other Safety InformationIMAP assessments - Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (50%)

毒性情報

Hepatotoxicity · 1 件

Prazosin has been associated with a low rate of serum aminotransferase elevations that in controlled trials was no higher than with placebo therapy. These elevations were transient and did not require dose modification. No instances of clinically apparent acute liver injury due to prazosin have been published in the literature, but reports of cholestatic hepatitis have been received by the sponsor. Among the alpha adrenergic receptor antagonists, the most frequently implicated agent in causing liver injury has been alfuzosin with only single, and not well documented cases linked to other alpha blockers. Thus, acute symptomatic liver injury due to prazosin is quite rare, and severe hepatotoxicity must be exceeding rare, if it occurs at all.

Adverse EffectsSerious Adverse Effects
Toxicity SummaryThere is no direct toxicity with this medication. High doses and overdoses could lead to hypotension, and patients should be supported clinically with volume resuscitation if necessary or pressor support.

化学と産業

薬理情報

ATC Code · 3 件

C02CA01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingHighly bound to proteins with 97% binding to albumin and alpha 1-acid glycoprotein. Prazosin is thought to be mostly (about 80-90%) bound to albumin.
Pharmacodynamics · 1 件

**Effects on blood pressure** The pharmacodynamic and therapeutic effect of this drug includes is a decrease in blood pressure as well as clinically significant decreases in cardiac output, heart rate, blood flow to the kidney, and glomerular filtration rate. The decrease in blood pressure may occur in both standing and supine positions. Many of the above effects are due to vasodilation of blood vessels caused by prazosin, resulting in decreased peripheral resistance,. Peripheral resistance refers to the level resistance of the blood vessels to blood that flows through them. As the blood vessels constrict (narrow), the resistance increases and as they dilate (widen), and peripheral resistance decreases, lowering blood pressure. **Effects on sleep disturbance related to post-traumatic stress disorder (PTSD)** Some studies have suggested that this drug improves sleep in patients suffering from insomnia related to nightmares and post-traumatic stress disorder, caused by hyperarousal. This effect likely occurs through the inhibition of adrenergic stimulation found in states of hyperarousal.

Mechanism of Action · 1 件

Alpha-adrenergic receptors are essential for the regulation of blood pressure in humans. Two types of alpha receptors, alpha 1 and alpha 2, both play a role in regulating blood pressure. Alpha-1 receptors are postsynaptic (located after the nerve junction, or space between a nerve fiber and target tissue). In this case, the target tissue is the vascular smooth muscle. These receptors, when activated, increase blood pressure. Prazosin inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation. Through blood vessel constriction by adrenergic receptor activation, epinephrine and norepinephrine normally act to increase blood pressure.

関連反応

10 件
反応記録を作成
HRID 372680 の反応式
HRID 372680生成物として
HRID 461331 の反応式
HRID 461331生成物として
HRID 461336 の反応式
HRID 461336生成物として
HRID 826660 の反応式
HRID 826660生成物として
HRID 840093 の反応式
HRID 840093生成物として
HRID 979728 の反応式
HRID 979728反応物として
HRID 1576327 の反応式
HRID 1576327生成物として
HRID 1580969 の反応式
HRID 1580969生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Prazosin USP/EP/BP
ART-CHEM-BB B020009
CHEBI:8364DTXCID0029008Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine2-[4-(2-Furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)-furan-2-ylmethanone[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-furan-2-ylmethanone2-(4-((furan-2-yl)carbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine

データベース識別子

CAS
19216-56-9
PubChem CID
4893
DTXSID
DTXSID4049082
ChEMBL
CHEMBL2
ChEBI
CHEBI:8364
UNII
XM03YJ541D
EC Number
242-885-8
Nikkaji
J10.000E
沸点
510.33 °C · 510.33°C (rough estimate)
比重(密度)
1.3275 · 1.3275 (rough estimate)
屈折率
1.76 · 1.7600 (estimate)
貯蔵温度
2 · 2-8°C
溶解性
DMSO(微量)、メタノール(微量、加温)
外見
個体
酸解離定数(Pka)
6.54 · pKa 6.54(50% EtOH) (Uncertain)
色
ホワイトからオフホワイト
水溶解度
3.2 mg/L · 3.2mg/L(22.5℃)
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
SMILES
C(N1CCN(C2=NC(N)=C3C(=N2)C=C(OC)C(OC)=C3)CC1)(C1=CC=CO1)=O
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

prazosin

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H315
Biological Half-Life
The plasma half-life is about 2-3 hours.
Metabolism/MetabolitesIn animals, prazosin hydrochloride is heavily metabolized. This occurs through liver demethylation and conjugation. Some studies in humans or human cells in vitro show similar prazosin metabolism.
FDA Pharmacological Classification · 6 件

XM03YJ541D

PRAZOSIN

Mechanisms of Action [MoA] - Adrenergic alpha-Antagonists

Established Pharmacologic Class [EPC] - alpha-Adrenergic Blocker

Prazosin is an alpha-Adrenergic Blocker. The mechanism of action of prazosin is as an Adrenergic alpha-Antagonist.

PRAZOSIN

MeSH Pharmacological Classification · 2 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Absorption, Distribution and Excretion · 4 件

After administration of an oral dose, peak plasma concentrations are attained at approximately 3 hours. There is a linear association between the prazosin dose given and plasma concentration at steady state.

This drug is mainly excreted in the bile and the feces.

About 0.6 L/kg.

In patients with congestive heart failure, the clearance of this drug is decreased. Impairment of renal function does not have relevant effects on elimination.

Cellular LocationsExtracellular

用途と製造

UsesUse (kg; approx.) in Germany (2009): >10
Use ClassificationPharmaceuticals
応用分野 · 3 件

用途α受容体遮断薬降圧効果

来歴Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.According to FDA, in October 2025, New Jersey-based drugmaker Teva Pharmaceuticals USA and drug distributor Amerisource Health Services issued voluntary nationwide recalls of over half a million bottles of various strengths of prazosine capsules, which may include a cancer-causing chemical.

使用Prazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output.

上流・下流製品情報

上流原料

1-(2-フリルカルボニル)ピペラジンベンゾニトリルAmmonia-ammonium chlorideヨードメタンチオ尿素アンモニア2-フロイルクロリド2-クロロ-6,7-ジメトキシキナゾリン-4-アミンピペラジン2,4-ジクロロ-6,7-ジヒドロ-5H-シクロペンタ[D]ピリミジン

下流製品

ブナゾシン

補足説明

定義ChEBI: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.